Soleus Capital Management, L.P. Blueprint Medicines Corp Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $1.88 Million - $2.55 Million	-20,454 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $1.36 Million - $1.9 Million	20,454 New	20,454 $1.9 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $1.27 Million - $2.17 Million	-26,400 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $1.76 Million - $2.18 Million	26,400 New	26,400 $2.11 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.